Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for D. Bruce Wheeler
-0.07 (-0.66%)
Real-time:   12:05PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.54 - 11.00
52 week 9.85 - 19.90
Open 10.63
Vol / Avg. 184,114.00/568,349.00
Mkt cap 557.51M
P/E     -
Div/yield     -
EPS -2.19
Shares 52.74M
Beta 1.78
Inst. own 81%
Aug 14, 2014
Momenta Pharmaceuticals Inc at Canaccord Genuity Growth Conference - 4:00PM EDT - Add to calendar
Jul 31, 2014
Q2 2014 Momenta Pharmaceuticals Inc Earnings Call - Webcast
Jul 31, 2014
Q2 2014 Momenta Pharmaceuticals, Inc. Earnings Release
Jun 17, 2014
Momenta Pharmaceuticals Inc at Wells Fargo Healthcare Conference
May 20, 2014
Momenta Pharmaceuticals, Inc. at UBS Global Healthcare Conference
May 13, 2014
Momenta Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
May 7, 2014
Momenta Pharmaceuticals, Inc. at Deutsche Bank Healthcare Conference - Webcast
May 6, 2014
Q1 2014 Momenta Pharmaceuticals, Inc. Earnings Conference Call - Webcast
May 6, 2014
Q1 2014 Momenta Pharmaceuticals, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -253.70% -305.68%
Operating margin -256.13% -309.01%
EBITD margin - -285.89%
Return on average assets -36.13% -29.97%
Return on average equity -42.41% -34.40%
Employees 269 -
CDP Score - -


675 West Kendall Street
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). This results in a diversified product pipeline of complex generic, follow-on biologic (FOB) and novel drugs. The Company�s complex generic programs target marketed products, which were originally approved by the United States Food and Drug Administration (FDA) as New Drug Applications (NDAs). Its M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). During the year ended December 31, 2011, it acquired the assets of Virdante. On February 13, 2012 it entered into a global collaboration (Baxter Agreement) with Baxter International Inc.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 62
Bio & Compensation  - Reuters
Michael Franken M.D. President - Biosimilars Business, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Bruce A. Leicher Esq. Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
John E. Bishop Ph.D. Senior Vice President - Pharmaceutical Sciences
Age: 52
Bio & Compensation  - Reuters
James M. Roach M.D. Senior Vice President - Development, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 60
Bio & Compensation  - Reuters
Bruce L. Downey Independent Director
Age: 67
Bio & Compensation  - Reuters